September 2014
Reactions Weekly;Sep2014, Vol. 1519 Issue 1, p34
The article presents a case study of a 51-year-old woman with posterior reversible encephalopathy syndrome which developed after treatment with bortezomib for multiple myeloma related with systemic amyloidosis and nephrotic syndrome.


Related Articles

  • Bortezomib.  // Reactions Weekly;Sep2014, Vol. 1519 Issue 1, p33 

    The article presents case studies of six patients aged 50-70 years who experienced chalazion which developed while receiving bortezomib for multiple myeloma.

  • Bortezomib.  // Reactions Weekly;Dec2014, Vol. 1532 Issue 1, p57 

    The article presents a case report of a patient who developed grade 3 diarrhoea during administration of bortezomib for treatment of multiple myeloma or light-chain amyloidosis.

  • Bortezomib.  // Reactions Weekly;May2015, Vol. 1553 Issue 1, p67 

    The article presents case studies of four men and three women aged 57-81 years who experienced infusion site reactions (ISRs) during therapy with bortezomib for multiple myeloma.

  • Bortezomib.  // Reactions Weekly;Nov2015, Vol. 1579 Issue 1, p86 

    The article describes the case of an 86-year-old man who developed extramedullary dissemination of myeloma due to resistant aggressive clone after bortezomib treatment for multiple myeloma, referencing research by G. Mele and colleagues, published in the journal "Clinical Lymphoma, Myeloma &...

  • Pomalidomide.  // AHFS Consumer Medication Information;Jun2020, p1 

    Pomalidomide is used alone and in combination with dexamethasone to treat multiple myeloma (a type of cancer of the bone marrow) that has not improved during or within 60 days of treatment with at least two other medications, including lenalidomide (Revlimid) and bortezomib (Velcade)....

  • Bortezomib.  // Reactions Weekly;1/15/2011, Issue 1334, p14 

    The article describes the case of a 65-year-old man who developed colitis while receiving the proteasome inhibitor bortezomib for multiple myeloma.

  • Towards a better understanding of the relationship between side effects of analgesia and quality of life in patients with multiple myeloma. Niscola, Pasquale; Siniscalchi, Agostina; Tendas, Andrea; de Fabritiis, Paolo; Caravita, Tommaso; Efficace, Fabio // Supportive Care in Cancer;Jan2016, Vol. 24 Issue 1, p9 

    A letter to the editor is presented in response to the article "Side effects of analgesia may significantly reduce quality of life in symptomatic multiple myeloma: a cross-sectional prevalence study" by S. Sloot and colleagues in the 2015 issue.

  • Draft document for ICER report on multiple myeloma drugs.  // PharmacoEconomics & Outcomes News;Feb2016, Vol. 746 Issue 1, p2 

    The article reports on a draft document for the Institute for Clinical and Economic Review (ICER) report on the treatment of refractory or relapsed multiple myeloma in adults using bortezomib, carfilzomib in combination with lenalidomide and dexamethasone, and daratumumab monotherapy.

  • Bortezomib.  // Reactions Weekly;9/22/2007, Issue 1170, p12 

    The article describes the case of a 62-year-old man who developed severe renal failure while receiving bortezomib for treatment-resistant multiple myeloma. He was given a 3-weekly regimen of bortezomib followed by a rest for 10 days. A slight increase in his serum creatinine level was noticed...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics